NCT01845584: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. |
|
|
| Completed | 2 | 7 | Japan | NPB-01, Intravenous immunoglobulin | Nihon Pharmaceutical Co., Ltd | Neuromyelitis Optica Spectrum Disorder | 08/15 | 08/15 | | |